In neoadjuvant chemotherapy, nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has shown a significant increase in the pathological complete response rate for breast cancer compared to solvent-based paclitaxel.[5] Additionally, the cost-effectiveness of nab-paclitaxel for breast cancer treatment surpasses that of other taxonomic drugs.[6] However, it is important to note that the incidence of TIPN and TIPN above grade 3 was significantly higher with nab-paclitaxel than with solvent-based paclitaxel (73% vs 46%, P < .001; 16% vs 5%, P < .001).[7]. Here, ALB is linked to breast carcinoma.